Immunophilin Ligands and Methods for Modulating Immunophilin and Calcium Channel Activity

• US 20100196355A1
• Filed: 01/29/2007
• Published: 08/05/2010
• Est. Priority Date: 01/29/2007
• Status: Abandoned Application

• Current Assignee: Wyeth LLC (Pfizer Inc.)
• Original Assignee: Wyeth (Pfizer Inc.)
• Inventors: Ruan, Benfang Helen, Bowlby, Mark Robert, Graziani, Edmund Idris, Pong, Kevin
• Application Number:
  US12/524,093
• Publication Number:
  US 20100196355A1
• Time in Patent Office: Days
• US Class Current: 424/130.1
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/552 one of the codrug's components being an antibiotic
• CPC Class Codes: A61P 13/06 Anti-spasmodics
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/06 Antimigraine agents
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/06 Antiarrhythmics
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: C07D 498/16 Peri-condensed systems
• CPC Class Codes: C07D 498/22 : in which the condensed system contains four or more hetero rings

Abstract

Immunophilin ligands and their uses as modulators of calcium channel activity are disclosed. Screening, therapeutic and prophylactic methods for conditions associated with calcium channel dysfunction, e.g., neurodegenerative and cardiovascular disorders, are also disclosed.

Claims

1. A purified complex comprising an immunophilin ligand, and one or both of (i) an immunophilin or a functional fragment thereof and/or (ii) a calcium channel subunit or a functional fragment thereof.

2. The purified complex of claim 1, wherein the immunophilin ligand is a rapamycin analogue having a heteroatom substituent at positions 1 and 4 of the rapamycin backbone.

3. The purified complex of claim 1, wherein the immunophilin ligand is a rapamycin analogue having the formula I:

4. The purified complex of claim 3, wherein R₁ of the rapamycin analogue is O, and R₂ is NR₃.

5. The purified complex of claim 3, wherein R₁ of the rapamycin analogue is OR₃ and R₂ is N(R_3′

)(NR_3″

).

6. The purified complex of claim 3, wherein R₃, R_3′

or R_3″

of the rapamycin analogue is an aryl or substituted aryl.

7. The purified complex of claim 6, wherein said aryl or substituted aryl of the rapamycin analogue is of the structure:

8. The purified complex of claim 1, wherein the immunophilin ligand is a rapamycin analogue selected from the group consisting of:

9. The purified complex of claim 1, wherein the immunophilin is FKBP52 or a functional fragment thereof having a sequence at least 95% identical, or identical, to the amino acid sequence shown in FIGS. 12A-12D (SEQ ID NO:

11-14).

10. The purified complex of claim 1, wherein the calcium channel subunit is a β

1 subunit of the voltage gated L-type calcium channel, or a functional fragment thereof, having a sequence at least 95% identical, or identical, to the amino acid sequence shown in FIGS. 11A-11J (SEQ ID NO;

1-10).

12. An antibody, or antigen-binding fragment thereof, that binds to the purified complex of claim 1.

11. A recombinant host cell comprising a first recombinant nucleic acid that comprises a nucleotide sequence encoding an FKBP52 having the amino acid sequence shown in FIGS. 12A-12D (SEQ ID NO:

11-14, and/or a second recombinant nucleic acid that comprises a nucleotide sequence encoding a β

1 subunit of the voltage gated L-type calcium channel having the amino acid sequence shown in FIGS. 11A-11J (SEQ ID NO;

1-10).

13. A method for identifying a test compound that increases the formation of a complex that includes the test compound, and one or both of (i) an immunophilin and/or (ii) a β

1 subunit of the voltage gated L-type calcium channel, comprising;

contacting an immunophilin or a functional fragment thereof, and/or a β

1 subunit or a functional fragment thereof, with a test compound under conditions that allow formation of the complex;

detecting the presence of the complex in the presence of the test compound relative to a reference;

wherein an increase in the level of the complex in the presence of the test compound, relative to the level of the complex in the reference, indicates that said test compound increases complex formation.

14. The method of claim 13, wherein the sample is a cell lysate, a reconstituted system, comprises cells in culture or in an animal subject.

15. The method of claim 13, wherein the increase in the formation of the complex is determined by detecting one or more of:

an increase in the physical formation of the complex, a change in signal transduction, a decrease in calcium channel activity or a change in neuronal activity.

16. The method of claim 15, wherein the change in neuronal activity is detected as an increase in one or more of survival, differentiation or neurite outgrowth.

17. The method of claim 13, wherein the test compound is a polyketide obtained from naturally occurring or modified S. hygroscopicus.

18. A compound identified by the method of claim 13.

56. Use of a compound identified according to any of claims 13-17 in the manufacture of a medicament for the prophylaxis or treatment of a condition associated with L-type calcium channel dysfunction.

59. A compound identified according to any of claims 13-17 for use in the prophylaxis or treatment of a condition associated with L-type calcium channel dysfunction.

19. A method of increasing the formation of a complex that includes an immunophilin ligand, and one or both of (i) an immunophilin or a functional variant thereof and/or (ii) a calcium channel subunit or a functional variant thereof, comprising:

contacting an immunophilin or a functional fragment thereof, and/or a β

1 subunit of the voltage gated L-type calcium channel or a functional fragment thereof, with an immunophilin ligand, under conditions that increase formation of the complex.

20. The method of claim 19, wherein the contacting step occurs in a cell lysate, in a reconstituted system, or cells in culture or in an animal subject.

21. A method of decreasing voltage-gated calcium channel activity, and/or FKBP52 activity, in a cell, comprising, contacting a cell that expresses one or both of an FKBP52 or a functional fragment thereof, and/or a β

1 subunit of the voltage gated L-type calcium channel or a functional fragment thereof, with an immunophilin ligand under conditions that allow binding between the immunophilin ligand, and one or both of the FKBP52 or fragment thereof, and/or the subunit or fragment thereof, to occur, thereby inhibiting the calcium channel activity.

22. The method of claim 21, wherein the contacting step comprises adding the immunophilin ligand to mammalian neuronal or cardiovascular cells in culture.

23. The method of claim 21, wherein the contacting step comprises administration to a subject the immunophilin ligand in an amount sufficient to form a complex between the immunophilin ligand, and one or both of the FKBP52 or fragment thereof, and/or the subunit or fragment thereof.

24. The method of claim 23, wherein the amount of the immunophilin administered to the subject is determined by testing in vitro the amount of immunophilin ligand required to induce complex formation.

25. The method of claim 23 further comprising identifying a subject at risk of having, or having, one or more symptoms associated with a disorder involving L-type calcium channel dysfunction.

26. The method of claim 23, wherein the subject is a mammal suffering from a neurodegenerative or a cardiovascular disorder.

27. The method of claim 23, wherein the immunophilin ligand is administered in combination with an L-type calcium channel antagonist.

28. The method of claim 23, wherein the immunophilin ligand is a rapamycin analogue having a heteroatom substituent at positions 1 and 4 of the rapamycin backbone.

29. The method of claim 28, wherein the rapamycin analogue has the formula I:

30. The method of claim 29, wherein the rapamycin analogue is selected from the group consisting of:

31. The method of claim 21, wherein the FKBP52 or a functional fragment thereof comprises an amino acid sequence at least 95% identical, or identical, to the amino acid sequence shown in FIGS. 12A-12D (SEQ ID NOs:

11-12).

32. The method of claim 21, wherein the β

1 subunit of the voltage gated L-type calcium channel, or a functional fragment thereof, comprises an amino acid sequence at least 95% identical to the amino acid sequence shown in FIGS. 11A-11J (SEQ ID NOs;

1-10).

33. A method of stimulating neurite outgrowth and/or survival of a neuronal cell, comprising, contacting the neuronal cell with an immunophilin ligand, wherein the immunophilin ligand is present at a concentration that elicits one or more of the following:

(i) downregulates expression or activity at least one component of the calcium signaling pathways;

(ii) decreases FKBP52 activity or expression;

(iii) reduces or inhibits the activity or expression of an L-type calcium channel;

(iv) activates glucocorticoid receptor signaling;

(v) induces formation of a complex that comprises the immunophilin ligand, FKBP52 and/or a β

1 subunit; and

/or (vi) protects neurons from calcium-induced cell death.

34. The method of claim 33, wherein the contacting step comprises administration to a subject of the immunophilin ligand in an amount sufficient to form the complex that comprises the immunophilin ligand, and one or both of FKBP52 and/or a β

1 subunit.

35. The method of claim 34, wherein the amount of the immunophilin administered to the subject is determined by testing in vitro the amount of immunophilin ligand required to induce complex formation.

36. The method of claim 33 further comprising identifying a subject at risk of having, or having, one or more symptoms associated with a disorder involving L-type calcium channel dysfunction.

44. The method of either claim 33 or 37, wherein the immunophilin ligand is a rapamycin analogue having the formula I:

45. The method of claim 44, wherein the rapamycin analogue is selected from the group consisting of:

46. The method of claim 44, wherein the immunophilin is FKBP52 or a functional fragment thereof having an amino acid sequence at least 95% identical, or identical, to 167 the amino acid sequence shown in FIGS. 12A-12D (SEQ ID NO:

11-14).

47. The method of claim 44, wherein the calcium channel subunit is a β

1 subunit of the voltage gated L-type calcium channel, or a functional fragment thereof having an amino acid sequence at least 95% identical, or identical, to the amino acid sequence shown in FIGS. 11A-11J (SEQ ID NO;

1-10).

37. A method of treating a disorder associated with L-type calcium channel dysfunction, comprising administering to a subject an immunophilin ligand in an amount sufficient to form a complex that includes the immunophilin ligand, and one or both of an immunophilin or a functional fragment thereof, and/or a calcium channel subunit or a functional fragment thereof, thereby treating the disorder.

38. The method of claim 37, wherein the amount of the immunophilin administered to the subject is determined by testing in vitro the amount of immunophilin ligand required to induce complex formation.

39. The method of claim 37, further comprising identifying a subject at risk of having, or having, one or more symptoms associated with a disorder involving L-type calcium channel dysfunction.

40. The method of claim 37, wherein the subject is a mammal suffering from a neurodegenerative or a cardiovascular disorder.

41. The method of claim 40, wherein the subject is a mammal suffering from a disorder selected from the group consisting of stroke, Parkinson'"'"'s disease, epilepsy, angina, cardiac arrhythmia and ischemia.

42. The method of claim 40, wherein the subject is a mammal suffering from a disorder selected from the group consisting of migraine, neuropathic pain, acute pain, mood disorder, schizophrenia, depression, anxiety, cerebellar ataxia, tardive dyskinesia, hypertension and urinary incontinence.

43. The method of claim 37, wherein the immunophilin ligand is administered in combination with an L-type calcium channel antagonist.

48. A method of stimulating neurite outgrowth of a neuronal cell, comprising contacting the neuronal cell with one or both of an antagonist of a β

1 subunit of a voltage gated L-type calcium channel, and/or an antagonist of FKBP52, under condition that reduce the activity or expression of the β

1 subunit or FKBP52.

49. The method of claim 48, wherein the neuronal cell is selected from the group consisting of a dopaminergic, a cholinergic, a cortical, and a spinal cord cell.

50. The method of claim 48, wherein the antagonist is an immunophilin ligand that forms a complex with the β

1 subunit and/or FKBP52.

51. The method of claim 48, wherein the antagonist is an inhibitor of transcription of the calcium channel β

subunit or FKBP52.

52. The method of claim 48, wherein the antagonist is an antibody.

53. Use of an immunophilin ligand in the manufacture of a medicament for the prophylaxis or treatment of a condition associated with L-type calcium channel dysfunction.

54. The use according to claim 53, wherein the immunophilin ligand is a rapamycin analogue having a heteroatom substituent at positions 1 and 4 of the rapamycin backbone.

55. Use of an immunophilin ligand in combination with an L-type calcium channel antagonist for the prophylaxis or treatment of a condition associated with L-type calcium channel dysfunction.

57. An immunophilin ligand for use in the prophylaxis or treatment of a condition associated with L-type calcium channel dysfunction.

58. A composition comprising an immunophilin ligand and an L-type calcium channel antagonist for use in the prophylaxis or treatment of a condition associated with L-type calcium channel dysfunction.